Storia in 2 fonti

Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513

The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion

Raccontata da

investors.com

qz.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

qz.comStai leggendo20 h fa

Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513

Amgen beat Q2: revenue +10% to $10.1B, EPS $6.29 vs expected $5.62, raising full-year guidance to $38.2–39.4B. Discontinued obesity candidate AMG 513; $3.5B free cash flow and portfolio discipline signal durable moat and M&A muscle in biotech consolidation.

originale

investors.com1 g fa

Amgen Boosts Sales View By $1 Billion After Smashing Views

Amgen smashed Wall Street's second-quarter expectations late Tuesday. Amgen stock topped a buy zone Wednesday.

Leggi questa versione → originale

Timeline cronologica

martedì 4 agosto 2026·investors.com
Amgen Boosts Sales View By $1 Billion After Smashing Views
Amgen smashed Wall Street's second-quarter expectations late Tuesday. Amgen stock topped a buy zone Wednesday.
mercoledì 5 agosto 2026·qz.com
Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513
The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion